Azacitidine

阿扎胞苷

Report date: 2026/04/23 20:00:25
NMEFirst In Class

Base Information

Drug NameAzacitidine
Drug Alias NameLadakamycin氮杂胞苷阿紮胞苷Azacytidine5-azacytidine +[18] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA (cytosine-5)-methyltransferase 1 inhibitors
TargetsDNA (cytosine-5)-methyltransferase 1
Therapy Area/IndicationsMetastatic breast cancerSkin MelanomaSolid tumours +[48] 
Global Approved IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute +[4] 
Approved Indications in ChinaMyelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date2004/05/19
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyWeill Medical College of Cornell UniversityKirby Institute +[16] 
Inactive CompaniesUtah State UniversityHeinrich Heine University DusseldorfTechnical University Of Denmark +[37] 
Active IndicationsImmune System DiseasesMyelodysplastic SyndromesCerebral Palsy +[13] 
Inactive IndicationsMetastatic breast cancerSkin MelanomaSolid tumours +[35] 

Other Information

ATC CodeL01BC07
Related LinksWikipediaDrugBankKEGG